Suppr超能文献

医用大麻或大麻素治疗慢性疼痛:临床实践指南。

Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.

机构信息

Michael G DeGroote Centre for Medicinal Cannabis Research, McMaster University, Hamilton, ON, Canada

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

出版信息

BMJ. 2021 Sep 8;374:n2040. doi: 10.1136/bmj.n2040.

Abstract

CLINICAL QUESTION

What is the role of medical cannabis or cannabinoids for people living with chronic pain due to cancer or non-cancer causes?

CURRENT PRACTICE

Chronic pain is common and distressing and associated with considerable socioeconomic burden globally. Medical cannabis is increasingly used to manage chronic pain, particularly in jurisdictions that have enacted policies to reduce use of opioids; however, existing guideline recommendations are inconsistent, and cannabis remains illegal for therapeutic use in many countries.

RECOMMENDATION

The guideline expert panel issued a weak recommendation to offer a trial of non-inhaled medical cannabis or cannabinoids, in addition to standard care and management (if not sufficient), for people living with chronic cancer or non-cancer pain.

HOW THIS GUIDELINE WAS CREATED

An international guideline development panel including patients, clinicians with content expertise, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach. The MAGIC Evidence Ecosystem Foundation (MAGIC) provided methodological support. The panel applied an individual patient perspective.

THE EVIDENCE

This recommendation is informed by a linked series of four systematic reviews summarising the current body of evidence for benefits and harms, as well as patient values and preferences, regarding medical cannabis or cannabinoids for chronic pain.

UNDERSTANDING THE RECOMMENDATION

The recommendation is weak because of the close balance between benefits and harms of medical cannabis for chronic pain. It reflects a high value placed on small to very small improvements in self reported pain intensity, physical functioning, and sleep quality, and willingness to accept a small to modest risk of mostly self limited and transient harms. Shared decision making is required to ensure patients make choices that reflect their values and personal context. Further research is warranted and may alter this recommendation.

摘要

临床问题

对于患有癌症或非癌症原因引起的慢性疼痛的患者,医用大麻或大麻素的作用是什么?

当前实践

慢性疼痛很常见且令人痛苦,并在全球范围内带来相当大的社会经济负担。医用大麻越来越多地用于治疗慢性疼痛,特别是在已经制定减少阿片类药物使用政策的司法管辖区;然而,现有的指南建议不一致,而且大麻在许多国家仍然被禁止用于治疗用途。

推荐意见

指南专家小组提出了一项弱推荐,即在标准护理和管理(如果不足)之外,为患有慢性癌症或非癌症疼痛的患者提供非吸入性医用大麻或大麻素的试用治疗。

本指南如何制定

一个国际指南制定小组,包括患者、具有专业内容的临床医生和方法学家,遵循 GRADE 方法制定了这一建议,符合可信指南的标准。MAGIC 证据生态系统基金会(MAGIC)提供了方法学支持。该小组采用了个体患者的视角。

证据

该建议是基于四项系统评价的综合,这些评价总结了当前有关医用大麻或大麻素治疗慢性疼痛的获益和危害、以及患者的价值观和偏好的证据。

理解建议

由于医用大麻治疗慢性疼痛的获益和危害之间的平衡非常接近,因此该建议是弱推荐。这反映了对自我报告的疼痛强度、身体功能和睡眠质量的小到非常小的改善,以及对大多自我限制和短暂的危害的适度风险的高度重视。需要进行共同决策,以确保患者做出反映其价值观和个人背景的选择。需要进一步的研究,这可能会改变这一建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验